SCHEMBL4138404

SCHEMBL4138404

O=S(=O)(OCC(F)(F)C(F)(F)F)c1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARL Q9H300 1/20 0.41
TDP1 Q9NUW8 2/20 0.37
HTR6 P50406 1/20 0.37
HSD11B1 P28845 2/20 0.37
PSIP1 O75475 1/20 0.36
PTGS2 P35354 1/20 0.36
ALDH1A1 P00352 4/20 0.36
KMT2A Q03164 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
APOBEC3G Q9HC16 1/20 0.35
RORC P51449 1/20 0.35
MAPK1 P28482 1/20 0.35
TSHR P16473 2/20 0.35
ABCC9 O60706 1/20 0.35
ABCC8 Q09428 1/20 0.35
KCNJ11 Q14654 1/20 0.35
KCNJ8 Q15842 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22265082 0.87 PARL (0.40) PARLTDP1HTR6HSD11B1PSIP1
SCHEMBL22265083 0.86 PARL (0.39) PARLTDP1HTR6HSD11B1PSIP1
SCHEMBL22265193 0.86 TDP1 (0.39) PARLTDP1HTR6PSIP1PTGS2
SCHEMBL22265192 0.86 PARL (0.39) PARLTDP1HTR6HSD11B1PSIP1
SCHEMBL2270234 0.85 CA1 (0.43) PARLTDP1HTR6HSD11B1PSIP1
SCHEMBL2533175 0.82 GAA (0.41) ALDH1A1KMT2ARORCMEN1CYP1A2
SCHEMBL22265195 0.80 PARL (0.35) PARLTDP1HSD11B1PTGS2ALDH1A1
SCHEMBL2058282 0.80 PARL (0.46) PARLTDP1HTR6HSD11B1PSIP1
SCHEMBL23456520 0.80 CA2 (0.44) HTR6HSD11B1ALDH1A1KMT2AKDM4E
SCHEMBL16863993 0.79 TSHR (0.41) PARLTDP1HTR6HSD11B1PSIP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 US disclosed
US-11760737-B2 Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine ADVERIO PHARM GmbH (DE) 2023-09-19 US disclosed
US-20220149436-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2022-05-12 US disclosed
US-20220089554-A1 PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE ADVERIO PHARMA GMBH (DE) 2022-03-24 US disclosed
US-11283107-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2022-03-22 US disclosed
EP-3914588-A1 PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE Adverio Pharma GmbH (DE) 2021-12-01 EP disclosed
WO-2020152010-A1 PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE ADVERIO PHARMA GMBH (DE) 2020-07-30 WO disclosed
EP-3621141-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2020-03-11 EP disclosed
US-20190229372-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2019-07-25 US disclosed
US-10333172-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2019-06-25 US disclosed
US-10290901-B2 2019-05-14 US disclosed
US-20170084955-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2017-03-23 US disclosed
US-20150056503-A1 NON-AQUEOUS LIQUID ELECTROLYTE AND NON-AQUEOUS LIQUID ELECTROLYTE SECONDARY BATTERY MITSUBISHI CHEMICAL CORPORATION (JP) 2015-02-26 US disclosed
EP-2012386-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE SECONDARY BATTERY Mitsubishi Chemical Corporation (JP) 2009-01-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089554-A1 PROCESS FOR MANUFACTURING 4-(2,2,3,3-TETRAFLUOROPROPYL)MORPHOLINE CYP4F3, CYP4F2, TNNT2 PARL 1536/4885TDP1 1375/4885HTR6 1455/4885
US-11760737-B2 Process for manufacturing 4-(2,2,3,3-tetrafluoropropyl)morpholine CYP4F3, CYP4F2, TNNT2 PARL 1536/4885TDP1 1375/4885HTR6 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.